Abstract:Abstract 4838 BACKGROUND: The aim of this study was to determine the safety, tolerance and efficacy of linezolid for the treatment of infections from Gram-positive bacteria in immunocompromised patients with Hematological Malignancy. METHODS: This was a prospective non-comparative unblinded and multi-center study in the Hematology Unit over a one-year period, administering combined use of linezolid in patients with Hematological Malignancy. RESULTS: Fifth-four adult patients received linezolid (600 mg, iv, q12h per day). Thirty-four children received linezolid (30 mg/kgr: 3 i.v. per day).Mean duration of linezolid administration was 12.8 days (range, 10–23days). Among the evaluable patients, fifty four were adults, the median age was 67(range, 30–101years); thirty four were children (range, 11 months-12.6 years), while the median age was 6 years. Primary diagnosis was acute lymphoblastic leukemia (forty-five patients), lymphoma (twenty-three patients), multiple myeloma (eleven patients), Aplastic anemia(four patients), myelodysplasia syndrome(one patients), leucopenia and hemophagocytic syndrome (two patient each). All patients were immunocompromised, 90% of them in the midst of chemotherapy cycles. The mean base number of platelet was 41×109/L(range, 30 – 138×109/L), platelet count less than 30×109/L patients were 28 cases (33%), among them, less than 10×109/L were 13 cases (14.8%). 27 out of 88 patients had positive blood cultures, methicillin-resistant Staphylococcus aureus, eighteen patients; Enterococcus, seven patients; Methicillin Resistant Staphylococcus Epidermidis and hemolytic streptococcus (one patient each).All patients were considered clinically cured after the end of the linezolid regimen (100% efficacy). The main adverse events were thrombocytopenia. There were 11 cases happened transient thrombocytopenia, Among them, four cases were happened within 4 days, seven cases happened four to seven days after received linezolid. Eliminate the possibility caused by reasons such as severe infection which can also result in thrombocytopenia, Linezolid related thrombocytopenia were only two cases (2.3%). Chemotherapy-induced myelotoxicity (90% patients) was not worsened during linezolid therapy. The platelet recovery time was also not lengthened during linezolid therapy. No bleeding episodes were presented, no Self-limited diarrhea were happened. The total adverse event rate was 2.3%; however, there was no premature cessation of linezolid in any patient. CONCLUSIONS: Linezolid may be another effective and safe therapy to treat infections from resistant Gram-positive bacteria in immunocompromised patients, even in children. Disclosures: No relevant conflicts of interest to declare.

Erysipelothrix rhusiopathiae bacteremia treated with linezolid

Progress on the Resistance Mechanism of Enterococcus to Linezolid

Epidemiological Characteristics and Genetic Structure of Linezolid-Resistant Enterococcus Faecalis

Emergence of cfr-harbouring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China.

Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy

The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

A case report of linezolid in treatment of Enterococcus faecalis meningitis patient

Successful treatment of chronic bone and joint infections with oral linezolid

Bacteremia Due to Rhodococcus Equi: A Case Report and Review of the Literature

Linezolid Resistance in Methicillin-Resistant Staphylococcus Epidermidis Strains Isolated in Hangzhou ;Area

A case of Corynebacterium striatum endocarditis successfully treated with an early switch to oral antimicrobial therapy

Oral Bacteria Dysbiosis in Patients with Linezolid-Induced Black Hairy Tongue: A Case Series

Successful Treatment of Pulmonary Nocardia Farcinica Infection with Linezolid: Case Report and Literature Review

Linezolid: a review of its use in the management of serious gram-positive infections

Linezolid Combined with Trimethoprim-Sulfamethoxazole Therapy for the Treatment of Disseminated Nocardiosis.

Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome

Linezolid in enterococcal urinary tract infection: a multicentre study

Nosocomial bloodstream infection and the emerging carbapenem-resistant pathogen Ralstonia insidiosa

Successful treatment of linezolid-induced severe lactic acidosis with continuous venovenous hemodiafiltration: A case report

Linezolid for the treatment of infections caused by Gram-positive pathogens in China

Linezolid and Rifampicin Combination to Combat Cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection